Literature DB >> 17410521

The construction of standard gamble utilities.

Sylvie M C van Osch1, Anne M Stiggelbout.   

Abstract

Health effects for cost-effectiveness analysis are best measured in life years, with quality of life in each life year expressed in terms of utilities. The standard gamble (SG) has been the gold standard for utility measurement. However, the biases of probability weighting, loss aversion, and scale compatibility have an inconclusive effect on SG utilities. We determined their effect on SG utilities using qualitative data to assess the reference point and the focus of attention. While thinking aloud, 45 healthy respondents provided SG utilities for six rheumatoid arthritis health states. Reference points, goals, and focuses of attention were coded. To assess the effect of scale compatibility, correlations were assessed between focus of attention and mean utility. The certain outcome served most frequently as reference point, the SG was perceived as a mixed gamble. Goals were mostly mentioned with respect to this outcome. Scale compatibility led to a significant upward bias in utilities; attention lay relatively more on the low outcome and this was positively correlated with mean utility. SG utilities should be corrected for loss aversion and probability weighting with the mixed correction formula proposed by prospect theory. Scale compatibility will likely still bias SG utilities, calling for research on a correction. Copyright (c) 2007 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2008        PMID: 17410521     DOI: 10.1002/hec.1235

Source DB:  PubMed          Journal:  Health Econ        ISSN: 1057-9230            Impact factor:   3.046


  15 in total

Review 1.  A Note on the Validity and Reliability of Multi-Criteria Decision Analysis for the Benefit-Risk Assessment of Medicines.

Authors:  Alberto Garcia-Hernandez
Journal:  Drug Saf       Date:  2015-11       Impact factor: 5.606

2.  Maximal endurable time states and the standard gamble: more preference reversals.

Authors:  P F M Stalmeier; A L Verheijen
Journal:  Eur J Health Econ       Date:  2012-12-09

3.  A decision analysis of amputation versus reconstruction for severe open tibial fracture from the physician and patient perspectives.

Authors:  Kevin C Chung; Melissa J Shauver; Daniel Saddawi-Konefka; Steven C Haase
Journal:  Ann Plast Surg       Date:  2011-02       Impact factor: 1.539

4.  Mastopexy for breast ptosis: Utility outcomes of population preferences.

Authors:  Ahmed Ms Ibrahim; Hani H Sinno; Ali Izadpanah; Joshua Vorstenbosch; Tassos Dionisopoulos; Mark K Markarian; Bernard T Lee; Samuel J Lin
Journal:  Plast Surg (Oakv)       Date:  2015       Impact factor: 0.947

Review 5.  Valuation of health states in the US study to establish disability weights: lessons from the literature.

Authors:  Jürgen Rehm; Ulrich Frick
Journal:  Int J Methods Psychiatr Res       Date:  2010-03       Impact factor: 4.035

6.  From a different angle: a novel approach to health valuation.

Authors:  Benjamin M Craig; Mark Oppe
Journal:  Soc Sci Med       Date:  2009-10-31       Impact factor: 4.634

7.  Measuring the effects of unintended pregnancy on women's quality of life.

Authors:  Eleanor Bimla Schwarz; Rachel Smith; Jody Steinauer; Matthew F Reeves; Aaron B Caughey
Journal:  Contraception       Date:  2008-07-22       Impact factor: 3.375

8.  A potential gender bias in assessing quality of life - a standard gamble experiment among university students.

Authors:  Leath Al Obaidi; Jörg Mahlich
Journal:  Clinicoecon Outcomes Res       Date:  2015-04-24

9.  The utility of outcome studies in plastic surgery.

Authors:  Hani Sinno; Tassos Dionisopoulos; Sumner A Slavin; Ahmed M S Ibrahim; Kevin C Chung; Samuel J Lin
Journal:  Plast Reconstr Surg Glob Open       Date:  2014-08-07

10.  Estimation of utility weights for major liver diseases according to disease severity in Korea.

Authors:  Minsu Ock; So Yun Lim; Hyeon-Jeong Lee; Seon-Ha Kim; Min-Woo Jo
Journal:  BMC Gastroenterol       Date:  2017-09-05       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.